3 results
The primary objective is to demonstrate the efficacy of AR101, a pharmaceutical-grade peanut allergen formulation, through reduction in clinical reactivity to limited amounts of peanut allergen in peanut-allergic children (ages 4-17 years, inclusive…
Primary:To assess the safety and tolerability of MCLA-117, in order to determine the MTD/RP2D and frequency of administration.Secondary:- To assess the pharmacokinetic (PK) profile of MCLA-117 i.v. infusion- To investigate the pharmacodynamic (PD)…
The primary objective of this study is to determine the safety, tolerability and efficacy of AR101 characterized oral desensitization immunotherapy (CODITTM) using alternative maintenance dosing intervals.The secondary objectives are:* To confirm…